BioShin

About:

BioShin is a clinical stage biopharmaceutical company.

Top Investors: OrbiMed, Cormorant Asset Management, Surveyor Capital, Suvretta Capital Management, HBM Healthcare Investments

Description:

BioShin is a wholly owned subsidiary of Biohaven Pharmaceuticals, a public biotech company. BioShin is a clinical stage biopharmaceutical company focused on developing medicines. It has proven leadership from global industry and academic settings and a portfolio of innovative, late stage product candidates targeting neurological and neuropsychiatric diseases, including rare disorders.

Total Funding Amount:

$60M

Headquarters Location:

Shanghai, Shanghai, China

Founded Date:

2013-01-01

Contact Email:

info(AT)bioshin.com

Founders:

Karl Lintel

Number of Employees:

1-10

Last Funding Date:

2020-09-28

IPO Status:

Private

Industries: